Literature DB >> 10544910

Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists.

B A Hutten1, M H Prins, W K Redekop, J G Tijssen, S H Heisterkamp, H R Büller.   

Abstract

During treatment with vitamin K antagonists, International Normalized Ratios (INR) are determined periodically to maintain a therapeutic level of anticoagulation. We evaluated two existing methods for therapeutic quality control (linear interpolation and equidivision), with regard to their validity and reproducibility. In addition, we proposed and evaluated a (hybrid) method that takes into account potential effects of dosage modifications when INRs are far out of the target range. Validity was assessed by deleting intermediary INR results and estimating this INR based on the two surrounding INRs with each of the three methods. The estimated INRs were then compared with the observed INR. Reproducibility of time spent in an INR range was evaluated for each of the three methods by deleting at random increasing proportions of INRs and comparing these estimates with the situation without deletions. We found that estimates of time spent in INR categories obtained with equidivision were most reproducible, but least valid. The hybrid method showed slightly higher validity and reproducibility in comparison with linear interpolation. Since these differences were small, linear interpolation is preferable to the hybrid method, since the calculations involved are easier.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10544910

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Authors:  Johanna H H van Geest-Daalderop; Barbara A Hutten; Augueste Sturk; Marcel M Levi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

2.  Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.

Authors:  Stephen E Kimmel; Benjamin French; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Yves D Rosenberg; Nancy L Geller; Scott E Kasner; Charles S Eby; Jungnam Joo; Michael D Caldwell; Samuel Z Goldhaber; Robert G Hart; Denise Cifelli; Rosemary Madigan; Colleen M Brensinger; Suzanne Goldberg; Robert M Califf; Jonas H Ellenberg
Journal:  Am Heart J       Date:  2013-07-12       Impact factor: 4.749

3.  Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

Authors:  M Jones; P McEwan; C Ll Morgan; J R Peters; J Goodfellow; C J Currie
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

4.  Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin.

Authors:  C J Currie; M Jones; J Goodfellow; P McEwan; C L Morgan; C Emmas; J R Peters
Journal:  Heart       Date:  2005-05-09       Impact factor: 5.994

5.  Anticoagulation control in the peri-hospitalization period.

Authors:  Carl van Walraven; Alan J Forster
Journal:  J Gen Intern Med       Date:  2007-03-31       Impact factor: 5.128

Review 6.  Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis.

Authors:  Natalie Oake; Alison Jennings; Alan J Forster; Dean Fergusson; Steve Doucette; Carl van Walraven
Journal:  CMAJ       Date:  2008-07-29       Impact factor: 8.262

7.  Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model.

Authors:  Johanna H H Van Geest-Daalderop; Barbara A Hutten; Nathalie C V Péquériaux; Marcel Levi; Augueste Sturk
Journal:  J Thromb Thrombolysis       Date:  2008-02-13       Impact factor: 2.300

8.  Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range.

Authors:  L Schmitt; J Speckman; J Ansell
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 9.  Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.

Authors:  Petra M G Erkens; Hugo ten Cate; Harry R Büller; Martin H Prins
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records.

Authors:  Gunnar H Nilsson; Ingela Björholt
Journal:  BMC Clin Pharmacol       Date:  2004-02-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.